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Background: Over 75% of the medical devices used in India are imported. Often, they are costly and maladapted
to low-resource settings. We have prepared case studies of six firms in Bangalore that could contribute to solving
this problem. They have developed (or are developing) innovative health care products and therefore are pioneers
in the Indian health care sector, better known for its reverse engineering skills. We have sought to understand what
enablers and barriers they encountered.
Methods: Information for the case studies was collected through semi-structured interviews. Initially, over 40
stakeholders of the diagnostics sector in India were interviewed to understand the sector. However the focus here
is on the six featured companies. Further information was obtained from company material and other published
resources.
Results: In all cases, product innovation has been enabled by close interaction with local medical practitioners, links
to global science and technology and global regulatory requirements. The major challenges were the lack of
guidance on product specifications from the national regulatory agency, paucity of institutionalized health care
payers and lack of transparency and formalized Health Technology Assessment in coverage decision-making. The
absence of national evidence-based guidelines and of compulsory continuous education for medical practitioners
were key obstacles in accessing the poorly regulated and fragmented private market.
Conclusions: Innovative Indian companies would benefit from a strengthened capacity and interdisciplinary work
culture of the national device regulatory body, institutionalized health care payers and medical councils and
associations. Continuous medical education and national medical guidelines for medical practitioners would
facilitate market access for innovative products.Background
In the case of drugs, due to its strong reverse enginee-
ring skills, India is virtually self-sufficient. In contrast,
75% of the annual purchase of devices and diagnostics
comes from imports [1]. A WHO report on medical
devices pointed out that: “almost all devices present
in developing countries have been designed for use in
industrialized countries” [2]. Consequently, they are
often unaffordable and are maladapted to low resource
settings.
Whereas rural health care providers are a documented
source of grassroots technical innovation on a micro* Correspondence: gayatri@ibab.ac.in
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distribution, and reproduction in any mediumscale [3] the private industry world-wide has valuable ex-
pertise in the development of medical devices for mass
use [2]. However, the industry has traditionally perceived
that developing-world markets are too small to justify
the development of new products [2,4]. Thus, over the
past decade, a number of push and pull incentives have
been proposed by international public health organi-
zations, non-governmental organizations (NGOs) and
donors in order to incentivize the western industry to
undertake research and development (R&D) addressing
the specific needs of the developing world [4,5], al-
though market access challenges of this industry in such
markets have been well-documented [6]. More recent is
health technology innovation, largely by young compan-
ies located in developing countries, where the companiesMed Central Ltd. This is an Open Access article distributed under the terms of
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strategy [7,8].
Important to health technology innovation is Health
Technology Assessment (HTA), defined as the “systematic
evaluation of the properties and effects of a health tech-
nology, addressing the direct and intended effects of this
technology, as well as its indirect and unintended conse-
quences, and aimed mainly at informing decision making
regarding health technologies” (http://htaglossary.net). In
industrialized countries, there is a growing interest in in-
teractions among bodies concerned with HTA, coverage
(institutional purchasing or reimbursement), and regula-
tion with whom the industry needs to engage in order to
develop novel products that can reach patients [9]. Im-
proving such interactions is believed “to speed patient
access to valuable products” and “to remove unnecessary
barriers to successful development and appropriate mar-
ket access for innovative products” [9].
In contrast, India doesn’t have a formalized national
HTA process and the public financing of new technolo-
gies is very limited [10]. Whereas 60-80% of health care
is delivered in the private sector, only 3-5% of the popu-
lation has health insurance [11] so coverage decisions by
insurers have negligible impact on the market uptake.
Further, medical practitioners in the private sector are
not obliged to follow any official evidence-based guide-
lines, and continuous medical education is not mandatory
[12-14]. Finally, the regulation of medical devices is min-
imal: in the case of in-vitro tests, only those for HIV, hepa-
titis B and C and blood typing are considered 'critical’ by
the Indian regulator and only these tests must be clinically
validated before receiving a license. In this context, our
study aimed to provide qualitative insights into the frugal
innovation experience of companies that function in an
environment that doesn’t have a tradition of indigenous
novel bio-medical product development.
Here we present case studies of six private companies
in Bangalore, India, that have developed and launched
(four cases) or are expecting to soon launch (two cases)
devices for the Indian market. These firms belong to a
new wave of intellectual property (IP)-based product ven-
tures in the country. We study (i) the evolution of the
firms and their approaches to product development; (ii)
their funding and human resource challenges; (iii) their
access to global science and technology (S&T); (iv) their
use of global regulatory requirements, and finally (v) the
market challenges that must be overcome in order to ac-
cess patients with their products. We believe that insights
from this study will be of interest to many young compan-
ies, regulators and policy makers in the world.
Methods
We adopted a qualitative case study research metho-
dology that has been used by others to study medicalinnovation in developing countries [8,15-17]. The in-
novative medical device industry in India is only emer-
ging today and a quantitative study would not be feasible
with such a small sample size. Further, as explained below,
the firms have gone through very different paths since
their inception and the case study methodology is better
suited to capture this heterogeneity. The study protocol
was approved by the Ethics Committee of IBAB. Written
informed consent was obtained from participants by
asking them to positively reply to an interview invitation
e-mail. Initially more than 40 private and government
doctors, diagnostic labs, manufacturers and distributors of
diagnostic tests, NGOs and academics were interviewed
about the diagnostics’ business in India. The interviews
concerned local innovation versus imported products, de-
livery of devices to patients in public and government sec-
tors, regulatory issues and doctors’ prescription behaviour.
Informants were chosen by purposeful sampling and were
chiefly located in metropolitan cities although their ex-
perience extended to rural areas as well. Results of these
interviews are not presented here, but served to select the
six companies located in Bangalore that were the basis for
this study. Additionally, the following sources were used:
the BioSpectrum India Life Sciences Resource Guide 2010
which is one of the most comprehensive repositories of in-
formation on the Indian life science industry (http://www.
newindigo.eu/biotech/main/index.htm) and a published
review of the Indian biotech industry [18]. Since none of
the firms had achieved significant sales at the time of our
research, financial measures such as profit, volumes or re-
turn on investment could not be used as criteria for selec-
tion. Nor were details of debt or equity available for the
(largely) privately held companies. We selected medical
device firms located in Bangalore, arguably the most in-
novative biomedical hub in India, that were developing in-
novative, IP-based products for the Indian market, and
low-resource settings in particular. Finally, in the one situ-
ation where two companies with similar profiles were
identified (that is, inception or origin, type of product and
development path) the company that was further in the
product development process was chosen. The company-
specific interviews sought to understand the inception of
the firm and the origin of the key personnel; the path of
product development and target product profiles; sources
of funding; issues related to clinical validation; regulatory
approval and market access in private and government
settings. Interviews were not recorded but detailed notes
were made during and immediately after each interview.
The analysis presented here is based on multiple inter-
views with the founders of five of the companies. In the
case of GE Healthcare India (GEH) the informant was the
senior product manager who led the development of
MAC400 and MACi. Consequently, the perspective of his
own R&D centre may not fully reflect the history of
Table 1 The six companies of this study, their year of
formation, their low cost products and the timelines for
(i) product concept, (ii) year of first patent being filed
and (iii) first sales in India
Company
(Year of formation)
Low cost products (Years of product concept,
first patent filed and first sales)
Xcyton (1993) • CheX: ELISA-based in vitro diagnostic (IVD) kit for
HIV patented by the company (1993; 1994;
1998). Technology for the remaining CheX kits
was in-licensed from academic institutions and
in one case from the Indian division of a
multinational company (MNC).
• XCyto Screen series: PCR-based IVD kits for rapid
diagnosis of infectious diseases (2003; 2006;
2011). XCyton owns the IP related to most of
the tests, although for the kits for eye infections
and sepsis it belongs to the Indian Council of
Scientific and Industrial Research which co-
financed the research. Also, patents are yet to
be filed for genotyping the Human Papilloma
Virus.
Bigtec (2000) • Micro-PCR device and reagents for low-
throughput, rapid, point-of-care in vitro
diagnosis of infectious diseases, suitable for
harsh conditions (2002; 2006; 2012 expected)
GEH (2000) • MACi: Portable ECG machine (2008; 2008; 2010)
ReaMetrix (2003) • Dry-Tri: Cold-chain independent and easy to use
CD4/CD8 assay reagent for HIV management,
suitable for harsh conditions (2004; no patent
filed; 2007).
• Fluorescence reader for CD4/CD8 assay (2007;
2011; 2011).
Embrace (2008) • Portable and safe infant warmer that helps to
preserve mother-child bonding and can work
for 4 hours without electricity. (2007; 2008; 2011)
Achira (2009) • Immunoassay-based microfluidic chips and
point-of-care device for low-throughput rapid
in vitro diagnosis (biochemistry), suitable for
low-resource settings (2009; 2009; external
validation planned)
• Immunoassay-based fabric chips for device-free,
point-of-care in vitro diagnosis of infectious
diseases (2010; 2010; internal optimisation
ongoing)
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interview at the company, followed by a few more conver-
sations in person, by phone or by e-mail. Further informa-
tion was obtained from company material and other
published interviews of the founders. After all the inter-
views, the write up on each of the six companies was veri-
fied by the concerned firm. However the final manuscript
was not submitted to them for their verification. All inter-
views were semi-structured and were conducted between
March and December 2011, inclusive.
Results
The companies and their products
The firms profiled are XCyton Diagnostics (XCyton),
Bigtec Labs (Bigtec), GEH, ReaMetrix India (ReaMetrix),
Embrace Global (Embrace) and Achira Labs (Achira).
The companies were founded from 2 to 18 years ago
(Table 1). Interestingly the founders of these six firms
came from six of the nine categories of biotech founders
in India, identified previously [18]. The earlier study had
pointed out a low rate of company formation by local
academics, and that is reflected here, where none is a
scientist from local academia (Additional file 1). In terms
of the companies’ evolution GEH started as a manu-
facturing support unit of GE Healthcare Worldwide's
Indian manufacturing facility and then evolved into an
R&D centre. The remaining ventures started as R&D
firms and this has remained unchanged (Additional file
2). Most of the firms were able to take their products
from concept to clinical validation in two to three years.
The exception was Bigtec where the founders operated
in a field that was unfamiliar to them, and where – when
the product launches later this year – it will have taken
12 years from the firm’s founding.
Each firm wanted its products to be appropriate for
use in low-resource settings which constitute the bulk of
the Indian market both in volume and in overall value.
Thus, each company undertook an independent assess-
ment of the needs of health-care providers in such set-
tings. It went on to construct product profiles according
to its own market- and consumer-research without guid-
ance from national health-care payers or regulators.
Low-cost was therefore a common criterion, although
other specifications varied with the company (Additional
file 3). Each firm’s route to its product(s) is outlined
below.
a. XCyton develops diagnostic kits for infectious
diseases. It has relied on (i) an invention sourced
from the local R&D centre of a multinational
company (MNC) (one case), or (ii) science sourced
from or products developed in collaboration with
Indian public or private research institutions (11
cases). These scientific collaborations were enabledby the personal contacts and informal links of the
founder to local scientists. They were unofficial
collaborations with low administrative burden and
great flexibility in negotiation. Initially, XCyton
developed ELISA-based kits (CheX) which require a
generic reader but are relatively easy to perform
even by untrained manpower. Later, the company
developed polymerase chain reaction (PCR)-based
kits (XCyto Screen) which call for skilled staff and
dedicated laboratory facilities. This shift from rapid
kits to high-resource technology was partially
motivated by fading confidence in the public health-
care market.
b. ReaMetrix started out as a contract research
organization (CRO) offering services to Western
Jarosławski and Saberwal BMC Health Services Research 2013, 13:199 Page 4 of 8
http://www.biomedcentral.com/1472-6963/13/199clients. This led to a gradual build up of its
capabilities and capacity. Subsequently the firm
changed track and developed a proprietary dried
reagent tailored to the needs of the National AIDS
Control Organization (NACO) program which
covers approximately 50% of the patients on anti-
retroviral treatment in India. This reagent is used for
a flow-cytometer-based test which monitors the
patient’s absolute CD4+ and CD8+ T-cell counts
and can replace a more expensive product supplied
to NACO by an MNC. Also, it (i) removes the
necessity of both cold-chain distribution (storage
and transport) and on-bench refrigeration and
(ii) reduces the possibility of procedural errors by
supplying the pre-weighed reagent in ready-to-use
disposable tubes. The company went on to develop a
cheaper, simpler and more robust fluorescence
reader that can replace the flow-cytometer that was
supplied to NACO by the MNC. The company
estimates that the currently used instrument costs
$20,000–90,000 and it is willing to offer its reader at
$15,000–20,000. In resource-limited settings it
would offer a reagent rental scheme wherein the
cost of ownership of the machine is zero. However,
disappointed with the government market, the
company is considering re-inventing itself yet again
to build advanced R&D instruments for Western
markets.
c. Initially Bigtec worked on a recombinant insulin for
the Indian market. Subsequently it shifted to an
innovative PCR-based microfluidics platform for the
detection of infectious diseases specific to India.
Notably, the founders were not microfluidics’
specialists. They were nevertheless attracted to this
technology because it offers the automation and
short sample processing times necessary in point-of
-care settings. The diagnostic device allows sample
preparation and mixing, bio-chemical reactions and
sample screening and detection to be performed on
a single chip. The diagnosis takes 45 minutes rather
than several hours, and can be performed in harsh
environmental conditions by an untrained person.
The technology has been clinically validated for
several diseases. Bigtec is planning to price the
device below the cost of a real-time PCR machine.
The cost of running a test would be similar to that
with a currently available in-vitro diagnostic (IVD)
kit for the concerned infection.
d. GEH started as a low cost, off-shored manufacturing
unit of the mother MNC. Subsequently, it developed
the MAC400 electrocardiogram (ECG) device for
emerging markets by removing some features from
an existing GE model. It was the first product
released for the Brazil, Russia, India and China(BRIC) markets and was priced at $800, compared
with GE’s other hospital-class ECG units that had a
price tag between $2,000 and $10,000. However, the
development of the next ECG device, MACi, was
specific to the Indian market. The needs of rural
health-care practitioners were surveyed by engineers
from several Indian states. This was felt to be a
necessity in a country with a multitude of local
languages, a range of geographies and wide
disparities in income-levels. It featured a fast-
charging, long-life battery and was robust and
portable. Also, the company realized that the
poorly-regulated local market was dominated by
very low-cost ECG machines, which was rather
unique among BRIC countries. MACi was therefore
priced at $500. It was released on the market just
one year after product conceptualization. The
emergence of GEH as an innovative product
development centre capable of the entire design,
development and manufacturing of a product was
enabled by two key factors: extensive supervision
and deliberate technology transfer from GE R&D
units located in Germany and the US, as well as the
initiative and corporate advocacy of a team at GEH
for the development of a product tailored to the
Indian market.
e. Embrace was set up to develop and commercialize a
portable and safe warmer for low-birth infants.
Although initially based in the US, it relocated to
India, where the core R&D team made field trips to
rural and urban settings in order to consult with
potential end-users. One version of the warmer has
been developed for use in hospitals and clinics. In
the former setting it facilitates the inter-ward
transfers of infants which might take up to 40
minutes. It is available for less than $300 compared
to $580–$1900 for currently used radiant warmers.
Another version is being developed for use at home
and in rural settings. In all settings, Embrace’s
warmers would replace potentially dangerous
electric radiators which can accidentally catch fire.
f. Achira was set-up to capitalize on the founder’s
academic expertise in microfluidics. Although it
started out intending to provide such services to
large global pharmaceutical companies, it soon
shifted focus to developing a lab-on-chip platform
for low-resource health-care providers in India.
Achira is developing two immunoassay-based
platforms: (i) microfluidic chips with a dedicated
fluorescence reader for quantitative assays and
(ii) device-free silk fibre-based chips for qualitative
assays, which can be read by the naked eye. The
former technology generates results in less than 30
minutes and can be used with minimal technical
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company and external validation is planned. The
latter technology is currently being optimized. It is
superior to the currently available lateral-flow
technology because multiple types of tests can be
performed on a single chip. Its large-scale
manufacture requires only low-cost physical
infrastructure and therefore it will be sold at a lower
price than the first platform.
In order to protect their inventions, all the firms filed
patents, in India and in other countries. There was a
general tendency to first file the applications in India
and then in the US and Europe. However, we formed the
impression that the young companies did not have an
established IP policy.Human resources
The Indian medical industry has traditionally been based
on reverse-engineering, and therefore many skills re-
quired for the development of entirely novel products
are rare in the country today [19]. Consequently the
companies faced a few challenges related to the recruit-
ment and retention of appropriately skilled personnel.
(i) Indians returning from Western nations, with post-
graduate academic degrees or industry experience, pla-
yed an important role in most of the firms (Additional
file 1). The process has been accelerated by both the re-
cent economic growth in urban India and the economic
stagnation of Western economies. (ii) All the firms have
found that neither candidates with experience in the
local pharmaceutical industry nor graduates of local
academic institutions have the right skill sets to work
on the design and marketing of innovative products.
Whereas senior scientific staff in the companies are able
to train new employees in technical skills, finding expe-
rienced candidates for market access activities has been
a key challenge. (iii) XCyton and Achira, which employ
Indian biologists with postgraduate experience, have
found that there are cultural issues related to retaining
their staff for long periods. As elsewhere, many biolo-
gists in India are women, and there is high attrition due
to the relocation of those who follow their spouses to
other cities. This churn has serious costs for young
firms, in terms of both time and money.Funding of the companies
The studied companies managed to engage with both
local and international investors to fund their R&D pro-
grams, without having to forgo majority equity. It turns
out that half of the firms were primarily funded from
Indian sources and the other half from foreign ones, as
detailed below (more details in Additional file 4).Primarily Indian sources
Among the indigenous start-ups, XCyton and Bigtec
benefitted from soft loans and small grants for young
R&D firms from the Government of India, and this
funding was vital. Both companies have had difficulty
finding investors who would be willing to fund marke-
ting and distribution activities without taking a majority
share. They perceive such offers as unfair since their pro-
ducts have already been clinically validated and therefore
the investment would carry relatively low risk. However,
XCyton has very recently obtained an equity investment
from a US-based entity which will be used mainly for mar-
keting its XCyto Screen services and also to establish new
laboratories across the country. Interestingly, this forced
the company to discontinue the two approved CheX tests
(for HIV and hepatitis C). This was necessary to avoid be-
ing classified as a pharmaceutical company under Indian
law and it enabled XCyton to finalize the foreign invest-
ment deal without government pre-approval.
Primarily Western sources
In contrast to the cases above, ReaMetrix was almost en-
tirely dependent on the private money of the founder
who has been a serial entrepreneur in the US, and on
international private investors. Although GEH is a divi-
sion of a global corporation, funds for the development
of an ECG for the local market were not granted auto-
matically. After the India-based team of engineers took
the initiative, their ideas received financial support first
from global headquarters and later from a locally created
budget. Finally, Embrace was established as a social
enterprise and was funded by US-based donors. The
founders are now planning to split the enterprise into a
non-profit and a for-profit entity, the latter in order to
secure the substantial international investment necessary
to enable large-scale manufacturing and global marketing.
Overall, the firms’ major struggle was in raising sub-
stantial funds for marketing as well as scaling-up ma-
nufacture. Apart from Bigtec which formed a product
marketing joint-venture with a major Indian diagnostics
manufacturer, the companies needed to rely on foreign
investment to finance such activities. Some of the firms
fear that an investment by an MNC would result in a
loss of control of the pricing strategy, and force them to
price their products higher than they would wish even in
low-resource settings.
Globalization of science and technology
Overall, the companies value being located in India. It
has allowed them to organize frequent field surveys,
construct meaningful product specifications and experi-
ment with market access strategies, all with respect to
low resource settings. Notably, however, each firm's abil-
ity to develop such appropriate technologies was enabled
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Western academia or industry (Table 2 and Additional
file 1). Contact with global S&T occurred in the local di-
visions of MNCs (XCyton and GEH) or through retur-
ning Indians (the other firms). Also, for some of the
firms, pre-existing international links were instrumental
in accessing Western clients and/or funding sources,
which were essential in the early days (Table 2). Since
the availability of manufacturers and suppliers of ad-
vanced services and components in India is limited, this
posed a challenge to several of the companies. Being a
division of an MNC, GEH has an international network
of accredited providers which facilitated sourcing of spe-
cific components. However other companies had to es-
tablish partnerships with industry located in Europe or
the US. These were often initiated during global charity
or industry meetings or through international academic
collaborations (Additional file 5). Thus, medical tech-
nology innovation in a developing country can require
outsourcing to the West due to the lack of local facilities
or expertise.
Experience with international regulatory authorities
The companies’ international reach concerns not only
S&T but also regulatory approval for their products.
This is mainly because the regulation of medical devices
in India is rudimentary. Further, the regulatory body is
not accustomed to licensing innovative products that
have not been approved in a developed country. Some
firms were dissatisfied with the limited regulation in the
country primarily for two reasons: (a) the lack of dia-
logue and guidance on what specifications a product
should meet and (b) unfair competition from manufac-
turers offering sub-standard and cheaper versions of
their innovative products.
In the absence of local regulation, the companies pur-
sued WHO pre-qualification, US Food and Drug Admin-
istration (FDA) approval or the CE mark (Additional file
4). It was considered necessary to engage with foreign
regulatory agencies not only for their guidance and to










GEH √ √ Not applicable
ReaMetrix √ √ √
Embrace √ √
Achira √substandard ones, but also for accessing global markets,
including those of low-income countries. Surprisingly, as
exemplified by the struggle of XCyton, even WHO pre-
qualification involves mobilizing significant resources.
Thus, whereas the company’s HIV CheX test was com-
pliant with WHO guidelines, pre-qualification came only
after a two-year effort to attract the attention of the re-
levant officer who was based in Geneva. Notably, this
contract gave XCyton global visibility. Subsequently, in-
ternational organizations have helped the firm obtain ac-
creditation abroad for other tests.
The firms have also pursued international certifica-
tions due to the high uncertainty related to the Indian
public market, that is discussed further below. The com-
panies that have tried to sell to the Indian government
have failed to do so. Therefore, the companies have ac-
cessed, or have considered accessing, the local market
via funding from foreign donor organizations. For this,
international accreditation of their products would be
required.
Accessing the market
Health-care providers in India range from high-end pri-
vate hospitals manned by highly qualified personnel and
equipped with the latest technologies, to public and pri-
vate rural health-care centres lacking trained staff and
with serious shortcomings in basic facilities such as the
availability of uninterrupted power and water. This has
large implications for the product planning process since
there is significant uncertainty regarding the kind of end
users and their sample throughput needs, as well as the
target price range. The companies’ perception is that
whereas high-end settings require high throughput ca-
pacity of an instrument and national or international
accreditation, other settings primarily require (i) low ca-
pital investment and maintenance costs, (ii) low costs to
the patient, (iii) resistance to adverse operating con-
ditions and (iv) the equipment should be explicitly
designed to facilitate task shifting to lower cadres of
workers. Consequently, the companies have found that
reaching such complex markets requires more time thanders’ or key persons’ prior links to Western industry or
Resources
Funding Access to clients Access to
suppliers
√ (for its sister IT company)
√ (division of an MNC) √
√ √ (in its CRO period)
√ (donations) √
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keting to high-resource settings in India proved insuffi-
cient to access low-resource settings with the MACi.
Thus, for the Indian market, the key obstacles to rea-
ching the customer have been: (a) an underfunded and
non-transparent government health-care market and (b)
a highly fragmented and poorly regulated for-profit pri-
vate market. In the case of diagnostics, soaring competi-
tion among diagnostic labs has increased the occurrence
of referral fees that are paid to doctors on a per patient
basis. It is also complex and costly to access African
countries, even via the WHO purchasing process. XCyton
and Embrace said that the largest funding rounds in
their existence would be used in large part for mar-
keting and distribution. These obstacles are discussed
in Additional file 6.
Discussion
Five of the six companies discussed here took their prod-
ucts from concept to validation in two to three years. This
compares well to the average product lifecycle of 18–24
months estimated by Eucomed, the medical technology
industry body in Europe (http://www.eucomed.org). How-
ever, the availability of both funding and the human re-
sources necessary to access the market with finished
products has been one of the major impediments to the
companies. Whereas advanced technological knowledge
could be accessed via links to global academic and indus-
try communities, the lack of local regulatory guidance
posed a major challenge for product development. Al-
though FDA, CE and WHO certifications are an alterna-
tive, the interviewed companies assert that the high cost
of such procedures and/or distant location of these agen-
cies are serious obstacles and result in delays. Whereas
there is scarcity of literature on the innovative health care
industry in India, some of these issues have been reported
previously [17,20]. Further, the paucity of institutional
health care payers, the fragmentation of private health-
care providers and the lack of national consensus guide-
lines meant that the companies had to use their own re-
sources to educate the doctors and laboratories about
their technologies. Notably, the for-profit nature of the
private sector demands that when pricing their products,
firms must consider both the affordability for the patient
and the provider’s desire to generate profits from the
provision of a technology [12,21-23]. This market com-
plexity implies that the commercial success and survival
of such companies will depend on their ability to develop
ground-breaking strategies in the post-R&D phase also.
Conclusions
We believe that the future of India’s innovative biome-
dical industry will depend on the upgradation of several
national policies. Whereas this study was not designedto inform such policies, and tools such as stakeholder
analysis are better suited for this purpose than the case
study method adopted here, we would like to make three
recommendations for the development of an innovative
medical device sector in India: First, the national regu-
latory bodies need to offer guidance to industry about
product development as the FDA, European Medicines
Agency and WHO do. Currently, the scientific capabil-
ities of the relevant agencies are inadequate to do this.
Second, government procurement of innovative devices
needs to be increased. Also, the process to do so should
be made more transparent through the incorporation
of explicit evidence-based decision making. The UK’s
National Institute for Health and Clinical Excellence and
similar government agencies in many other European
and some Asian countries, such as Japan, Singapore and
Malaysia, appraise medical technologies and advise on
their financing from public sources. Third, the private
healthcare sector requires more regulation. This implies
tackling the issue of referral fees and the production of
national guidelines for diagnosis and treatment. In many
countries that have nationalised health systems this is
achieved through close collaboration between the HTA
bodies, medical councils that control doctors’ practice
and the national health funds or insurers that directly
employ most health care professionals. However, it re-
mains to be seen whether such centralized control can
or should be achieved in a large and diverse country
such as India, that has a health care sector that is highly
fragmented and largely private.Additional files
Additional file 1: Detailed profiles and origins of the founders and
key people in the studied companies.
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